Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16069463 | 0.88 | PRKAG1 (0.44) | PTGS2CNR1USP28 | |
| SCHEMBL17391551 | 0.86 | CNR1 (0.40) | PTGS2CNR1USP28 | |
| SCHEMBL17402604 | 0.84 | HAVCR2 (0.39) | — | |
| SCHEMBL23967852 | 0.81 | PRKAG1 (0.45) | — | |
| SCHEMBL17402603 | 0.78 | PRKAG1 (0.40) | PTGS2CNR1 | |
| SCHEMBL17402613 | 0.78 | PTGS2 (0.40) | PTGS2CNR1PTGS1SCD | |
| SCHEMBL16069446 | 0.78 | PTGS2 (0.40) | PTGS2CNR1SCD | |
| SCHEMBL23967834 | 0.78 | PTGS2 (0.47) | PTGS2CNR1PTGS1SCD | |
| SCHEMBL16069683 | 0.78 | PRKAG1 (0.41) | — | |
| SCHEMBL17402637 | 0.78 | PRKAB2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650375-B2 | Indole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160002224-A1 | NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME LLC | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002224-A1 | NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | GPR119, PRKAG2, PRKAG1 | PTGS2 292/4885CNR1 1481/4885PTGS1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.